MorphoSys (ETR:MOR) has been assigned a €135.00 ($156.98) price objective by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Monday. The firm currently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 34.33% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Royal Bank of Canada set a €65.00 ($75.58) price target on shares of MorphoSys and gave the company a “sell” rating in a research report on Monday, October 1st. Oddo Bhf set a €116.00 ($134.88) price target on shares of MorphoSys and gave the company a “buy” rating in a research report on Monday, November 19th. Goldman Sachs Group set a €86.00 ($100.00) price target on shares of MorphoSys and gave the company a “neutral” rating in a research report on Wednesday, September 26th. Commerzbank set a €107.00 ($124.42) price target on shares of MorphoSys and gave the company a “neutral” rating in a research report on Tuesday, November 6th. Finally, Deutsche Bank set a €130.00 ($151.16) price target on shares of MorphoSys and gave the company a “buy” rating in a research report on Monday, December 10th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of €102.60 ($119.30).

MOR stock opened at €100.50 ($116.86) on Monday. MorphoSys has a 12-month low of €49.63 ($57.71) and a 12-month high of €88.10 ($102.44).

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

See Also: Treasury Bonds

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.